SRINAGARIND MEDICAL JOURNALVolume 36, No. 04, Month JULY, Year 2021, Pages 438 - 443
Production of truncated recombinant dengue virus envelope protein and its immunogenicity in balbc mice
Chonlatip Pipattanaboon, Piyathida Natsrita, Khwanchit Boonha, Surachet Benjathummarak, Pannamthip Pitaksajjakul, Pongrama Ramasoota
Abstract Download PDFBackground and objective: Dengue is a major public
health problem in tropical and subtropical countries.
The four dengue virus serotypes can cause a wide
range of mild to severe diseases. Many research and
development efforts are ongoing to find a better
effective and accessible version of vaccine,
therapeutic agent, or diagnostic tool. Envelope (E)
protein is a primary target for serologic diagnosis and
immunization. This work aimed to express and
characterize truncated E (rE74-118) protein of dengue
virus serotype 2 (DENV-2) in both in vitro and in vivo
Methods and results: A truncated DENV-2 envelope
E protein, amino acid sequence 74-118, encoding gene
was amplified and cloned into the pET-32b plasmid.
The recombinant plasmid was then expressed in
Escherichia coli (SHuffle) to produce the recombinant
protein rE74-118. Recombinant E protein in truncated
form (rE74-118) was successfully constructed,
expressed, and purified in the concentration of 5.8
mg/ml. The rE74-118 protein was tested for its specificity with an anti-E monoclonal antibodies and
dengue patient sera. Furthermore, its immunogenicity
in BALB/c mice was also tested. The results showed
that the rE74-118 protein can specifically react to
anti-E monoclonal antibodies and dengue patient sera.
This protein also induces the humoral response with
a low-level of neutralizing activity against DENV-2, as
well as the protein do not show enhancing activities
against all four serotypes.
Conclusion: The truncated rE74-118 protein showed
both antigenic and immunogenic properties in these
in vitro and in vivo characterizations.
Dengue virus; truncated envelope protein; antigen; immunogen